Pediatric Drugs

, Volume 9, Issue 1, pp 11–16

Paroxysmal Nocturnal Hemoglobinuria in Children

Leading Article


Paroxysmal nocturnal hemoglobinuria (PNH), an acquired hematologic disorder characterized by intravascular hemolysis, nocturnal hemoglobinuria, thrombotic events, serious infections, and bone marrow failure, is very rare in children. PNH is caused by a somatic mutation of the phosphatidylinositol glycan (GPI) complementation class A (PIGA) gene, followed by a survival advantage of the PNH clone, which results in a deficiency of GPI-anchored proteins on hematopoietic cells.

Currently, immunophenotypic GPI-linked anchor protein analysis has replaced the acid Ham and sucrose lysis test, as it provides a reliable diagnostic tool for this disease. The presence of PNH clones should be considered in every child with an acquired bone marrow failure syndrome, for example (hypoplastic) myelodysplastic syndrome and aplastic anemia, and/or unexpected serious thrombosis.

Treatment of PNH in children is dependent on the clinical presentation. In cases of severe bone marrow failure, stem cell transplantation should be seriously considered as a therapeutic option even if no matched sibling donor is available. This article reviews the reported cases of PNH in children using the recently published guidelines for classification, diagnostics, and treatment.


  1. 1.
    Strübing P. Paroxysmale hämoglobinurie. Deutsche Medicinische Wochenschrift 1882; 8: 17–21CrossRefGoogle Scholar
  2. 2.
    Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: ‘defining the disease’. Br J Haematol 2002; 117(1): 3–22PubMedCrossRefGoogle Scholar
  3. 3.
    Low MG, Finean JB. Release of alkaline phosphatase from membranes by a phosphatidylinositol-specific phospholipase C. Biochem J 1977; 167: 281–4PubMedGoogle Scholar
  4. 4.
    Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993; 259(5099): 1318–20PubMedCrossRefGoogle Scholar
  5. 5.
    Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73(4): 703–11PubMedCrossRefGoogle Scholar
  6. 6.
    Nishimura J, Phillips KL, Ware RE, et al. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. Blood 2001; 97(10): 3004–10CrossRefGoogle Scholar
  7. 7.
    Karadimitris A, Luzzatto L. The cellular pathogenesis of paroxysmal nocturnal haemoglobinuria. Leukemia 2001; 15(8): 1148–52PubMedCrossRefGoogle Scholar
  8. 8.
    Risitano AM, Holada K, Chen G, et al. CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion proein (PrPc). Exp Hematol 2003; 31: 65–72PubMedCrossRefGoogle Scholar
  9. 9.
    Rizk S, Ibrahim IY, Mansour IM, et al. Screening for paroxysmal nocturnal hemoglobinuria (PNH) clone in Egyptian children with aplastic anemia. J Trop Pediatr 2002; 48(3): 132–7PubMedCrossRefGoogle Scholar
  10. 10.
    Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med 1991; 325(14): 991–6PubMedCrossRefGoogle Scholar
  11. 11.
    Meletis J, Terpos E. Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria. Med Sci Monit 2003; 9(7): RA161–72PubMedGoogle Scholar
  12. 12.
    Flotho C, Strahm B, Kontny U, et al. Stem cell transplantation for paroxysmal nocturnal haemoglobinuria in childhood. Br J Haematol 2002; 118(1): 124–7PubMedCrossRefGoogle Scholar
  13. 13.
    Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106(12): 3699–709PubMedCrossRefGoogle Scholar
  14. 14.
    Wainwright L, Brodsky RA, Erasmus LK, et al. Paroxysmal nocturnal hemoglobinuria arising from Fanconi anemia. J Pediatr Hematol Oncol 2003; 25(2): 167–8PubMedCrossRefGoogle Scholar
  15. 15.
    Nathan D, Oski F. Nathan and Oski’s hematology of infancy and childhood. 6th ed. Philadelphia (PA): W.B. Saunders, 2003Google Scholar
  16. 16.
    Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108(3): 470–9PubMedCrossRefGoogle Scholar
  17. 17.
    Young NS, Maciejewski JP. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes ‘Why? Why? Why?’ J Clin Invest 2000; 106(5): 637–41CrossRefGoogle Scholar
  18. 18.
    Karadimitris A, Manavalan JS, Thaler HT, et al. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 2000; 96(7): 2613–20PubMedGoogle Scholar
  19. 19.
    Takahashi Y, McCoy Jr JP, Carvallo C, et al. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood 2004; 103(4): 1383–90PubMedCrossRefGoogle Scholar
  20. 20.
    Hall C, Richards SJ, Hillmen P. The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model. Acta Haematol 2002; 108(4): 219–30PubMedCrossRefGoogle Scholar
  21. 21.
    Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 2000; 42(4): 223–33PubMedCrossRefGoogle Scholar
  22. 22.
    Mortazavi Y, Merk B, McIntosh J, et al. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood 2003; 101(7): 2833–41PubMedCrossRefGoogle Scholar
  23. 23.
    Nafa K, Bessler M, Castro-Malaspina H, et al. The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis 1998; 24(3): 370–84PubMedCrossRefGoogle Scholar
  24. 24.
    Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100(12): 3897–902PubMedCrossRefGoogle Scholar
  25. 25.
    Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131(6): 401–8PubMedGoogle Scholar
  26. 26.
    van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol 2005; 128(4): 571–7PubMedCrossRefGoogle Scholar
  27. 27.
    Miller DR, Baehner RL, Diamond LK. Paroxysmal nocturnal hemoglobinuria in childhood and adolescence: clinical and erythrocyte metabolic studies in two cases. Pediatrics 1967; 39(5): 675–88PubMedGoogle Scholar
  28. 28.
    Kletzel M, Arnold WC, Berry DH. Paroxysmal nocturnal hemoglobinuria presenting as recurrent hemolytic uremic syndrome. Clin Pediatr (Phila) 1987; 26(6): 319–20CrossRefGoogle Scholar
  29. 29.
    Wyatt HA, Mowat AP, Layton M. Paroxysmal nocturnal haemoglobinuria and Budd-Chiari syndrome. Arch Dis Child 1995; 72(3): 241–2PubMedCrossRefGoogle Scholar
  30. 30.
    Graham ML, Rosse WF, Halperin EC, et al. Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1996; 92(3): 707–10PubMedCrossRefGoogle Scholar
  31. 31.
    Endo M, Beatty PG, Vreeke TM, et al. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood 1996; 88(2): 742–50PubMedGoogle Scholar
  32. 32.
    Lin HC, Chen RL, Wang PJ. Paroxysmal nocturnal hemoglobinuria presenting as moyamoya syndrome. Brain Dev 1996; 18(2): 157–9PubMedCrossRefGoogle Scholar
  33. 33.
    Hill A, Ridley SH, Esser D, et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood 2006; 107(5): 2131–7PubMedCrossRefGoogle Scholar
  34. 34.
    Parker CJ. An overview of specific inhibitors of complement: opportunities for therapy of paroxysmal nocturnal hemoglobinuria and related disorders. In: Omine M, Kinoshita T, eds. Paroxysmal nocturnal hemoglobinuria and related disorders: molecular aspects of pathogenesis. Tokyo: Springer, 2003: 11–23CrossRefGoogle Scholar
  35. 35.
    Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350(6): 552–9PubMedCrossRefGoogle Scholar
  36. 36.
    Hill A, Rother RP, Hillmen P. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. E-case Haematologica 2005; 90: ECR40Google Scholar
  37. 37.
    Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005; 106(7): 2559–65PubMedCrossRefGoogle Scholar
  38. 38.
    Issaragrisil S, Piankijagum A, Tang-naitrisorana Y. Corticosteroids therapy in paroxysmal nocturnal hemoglobinuria. Am J Hematol 1987; 25(1): 77–83PubMedCrossRefGoogle Scholar
  39. 39.
    Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood 1982; 60(1): 20–3PubMedGoogle Scholar
  40. 40.
    Hartmann RC, Jenkins Jr DE, McKee LC, et al. Paroxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy with androgen and iron. Medicine (Baltimore) 1966; 45(5): 331–63CrossRefGoogle Scholar
  41. 41.
    Monagle P, Chan A, Massicotte P, et al. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 645S–87SPubMedCrossRefGoogle Scholar
  42. 42.
    Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003; 102(10): 3587–91PubMedCrossRefGoogle Scholar
  43. 43.
    Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348(9027): 573–7PubMedCrossRefGoogle Scholar
  44. 44.
    Antin JH, Ginsburg D, Smith BR, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood 1985; 66(6): 1247–50PubMedGoogle Scholar
  45. 45.
    Storb R, Evans RS, Thomas ED, et al. Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation. Br J Haematol 1973; 24(6): 743–50PubMedCrossRefGoogle Scholar
  46. 46.
    Epperson DE, Nakamura R, Saunthararajah Y, et al. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001; 25(12): 1075–83PubMedCrossRefGoogle Scholar
  47. 47.
    Inukai T, Sugita K, Goto M, et al. Spontaneous recovery from pancytopenia in a young female patient with paroxysmal nocturnal hemoglobinuria (PNH): changes in the GPI-anchor expression on peripheral blood cells. Rinsho Ketsueki 2004; 45(3): 238–42PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of Pediatric Oncology/HematologyErasmus Medical Center-Sophia Children’s HospitalRotterdamThe Netherlands

Personalised recommendations